Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

To evaluate the efficacy and safety of neoadjuvant and adjuvant Sintilimab combined with chemoradiotherapy versus chemoradiotherapy alone in stage TanyN3M0 nasopharyngeal carcinoma. The primary endpoint was 2-year failure-free survival (FFS). Secondary endpoints included 2-year overall survival (OS), distant failure-free survival (DFFS), locoregional failure-free survival (LRFFS), and adverse events.

NCT Number	NCT06680115
Lead Sponsor	First Affiliated Hospital of Guangxi Medical University
Conditions	Nasopharyngeal Carcinoma (NPC)
Enrollment	150 participants
Start Date	2024-11
Primary Completion	2026-12 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2024-11-08